4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Divi's Laboratories Limited (DIVISLAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 11,565 employees. Its market capitalization is roughly ₹2.49 trillion. In the fiscal year ended 2026-03-31, DIVISLAB reported ₹104.8B in revenue and ₹25.7B in net income.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | ₹104.8B | ₹93.2B | ₹78.0B | ₹76.7B |
| Gross Profit | ₹62.0B | ₹54.5B | ₹45.3B | ₹44.9B |
| Operating Income (EBIT) | ₹29.8B | ₹25.7B | ₹18.3B | ₹20.3B |
| Net Income | ₹25.7B | ₹21.9B | ₹16.0B | ₹18.2B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹30.8B | ₹28.3B | ₹26.0B | ₹24.1B | ₹25.9B |
| Gross Profit | ₹20.9B | ₹17.1B | ₹16.6B | ₹14.5B | ₹16.0B |
| Operating Income (EBIT) | ₹11.2B | ₹8.1B | ₹7.7B | ₹6.2B | ₹7.8B |
| Net Income | ₹9.0B | ₹7.5B | ₹5.8B | ₹5.5B | ₹6.6B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹8.0B) | (₹8.0B) | (₹8.0B) | (₹8.0B) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹200.3B | ₹169.3B | ₹154.7B | ₹144.4B | — |
| Total Liabilities | ₹32.7B | ₹19.6B | ₹19.0B | ₹16.7B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DIVISLAB viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms